Related Experiment Video
Updated: Mar 10, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.5K
[Fast-acting insulin - new developments towards more flexibility for the patient]
Gerhard W Schmeisl1,2, Yasmin Kretzschmar3
1Medizin/Angiologie/Rehabilitationswesen/Sportmedizin/Diabetologe DDG/Sozialmedizin, Deegenbergklinik und Saale Klinik ( DRV-Bund), Bad Kissingen, Deutschland. schmeisl@deegenberg.de.
MMW Fortschritte Der Medizin
|December 10, 2016
Summary
New ultra-rapid acting insulins aim to mimic natural insulin secretion for better type 2 diabetes management. These advancements improve post-prandial glucose control and offer patients more mealtime flexibility.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Physiological post-prandial insulin secretion is rapid and in adequate concentrations.
- This mechanism is impaired in type 2 diabetes, leading to hyperglycemia.
- Exogenous insulin needs rapid absorption and quick Cmax to mimic physiological conditions.
Purpose of the Study:
- To review the development of new bolus insulins with improved pharmacokinetic and pharmacodynamic properties.
- To highlight innovations in insulin formulations, delivery sites, and systems.
- To discuss the impact of faster-acting insulins on glucose control and patient flexibility.
Main Methods:
- Review of recent advancements in insulin development.
- Investigation of novel pharmaceutical formulations.
- Exploration of different insulin application sites and delivery systems.
Main Results:
- Development of ultra-fast acting bolus insulins.
- Innovations in formulations and delivery methods enhance insulin absorption.
- New insulins demonstrate improved pharmacokinetic and pharmacodynamic profiles.
Conclusions:
- Faster-acting insulins offer improved post-prandial glucose control for type 2 diabetes patients.
- These innovations provide greater flexibility in meal planning.
- Continued research focuses on optimizing insulin therapy for better metabolic outcomes.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
923
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
923
01:16Insulin: Dosing Regimen and Adverse Effects
1.0K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.0K
01:06Oral Hypoglycemic Agents: Glinides
789
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
789
01:24Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
01:25Insulin: Biosynthesis, Chemistry, and Preparation
1.7K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.7K
01:23Dipeptidyl Peptidase 4 Inhibitors
836
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
836